Tissue | Expression Dynamics | Abbreviation |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/PHB_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PHB_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PHB_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PHB_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PHB_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PHB_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PHB_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00703718 | Thyroid | HT | ERK1 and ERK2 cascade | 39/1272 | 330/18723 | 5.27e-04 | 6.31e-03 | 39 |
GO:003367426 | Thyroid | HT | positive regulation of kinase activity | 51/1272 | 467/18723 | 5.42e-04 | 6.46e-03 | 51 |
GO:003052120 | Thyroid | HT | androgen receptor signaling pathway | 10/1272 | 44/18723 | 5.97e-04 | 6.95e-03 | 10 |
GO:00421133 | Thyroid | HT | B cell activation | 39/1272 | 334/18723 | 6.66e-04 | 7.61e-03 | 39 |
GO:19012249 | Thyroid | HT | positive regulation of NIK/NF-kappaB signaling | 13/1272 | 69/18723 | 6.70e-04 | 7.61e-03 | 13 |
GO:00459269 | Thyroid | HT | negative regulation of growth | 31/1272 | 249/18723 | 8.02e-04 | 8.75e-03 | 31 |
GO:00027648 | Thyroid | HT | immune response-regulating signaling pathway | 50/1272 | 468/18723 | 9.96e-04 | 1.02e-02 | 50 |
GO:19012226 | Thyroid | HT | regulation of NIK/NF-kappaB signaling | 17/1272 | 112/18723 | 1.44e-03 | 1.36e-02 | 17 |
GO:00429214 | Thyroid | HT | glucocorticoid receptor signaling pathway | 5/1272 | 14/18723 | 1.71e-03 | 1.55e-02 | 5 |
GO:00396945 | Thyroid | HT | viral RNA genome replication | 8/1272 | 35/18723 | 2.00e-03 | 1.77e-02 | 8 |
GO:003582116 | Thyroid | HT | modulation of process of other organism | 16/1272 | 106/18723 | 2.09e-03 | 1.84e-02 | 16 |
GO:00319584 | Thyroid | HT | corticosteroid receptor signaling pathway | 5/1272 | 15/18723 | 2.43e-03 | 2.05e-02 | 5 |
GO:00486608 | Thyroid | HT | regulation of smooth muscle cell proliferation | 23/1272 | 180/18723 | 2.57e-03 | 2.15e-02 | 23 |
GO:004586020 | Thyroid | HT | positive regulation of protein kinase activity | 41/1272 | 386/18723 | 3.01e-03 | 2.43e-02 | 41 |
GO:00486598 | Thyroid | HT | smooth muscle cell proliferation | 23/1272 | 184/18723 | 3.40e-03 | 2.63e-02 | 23 |
GO:00380617 | Thyroid | HT | NIK/NF-kappaB signaling | 19/1272 | 143/18723 | 3.77e-03 | 2.81e-02 | 19 |
GO:00703726 | Thyroid | HT | regulation of ERK1 and ERK2 cascade | 34/1272 | 309/18723 | 3.77e-03 | 2.81e-02 | 34 |
GO:003051825 | Thyroid | HT | intracellular steroid hormone receptor signaling pathway | 16/1272 | 116/18723 | 5.21e-03 | 3.48e-02 | 16 |
GO:00026975 | Thyroid | HT | regulation of immune effector process | 36/1272 | 339/18723 | 5.22e-03 | 3.49e-02 | 36 |
GO:007189719 | Thyroid | HT | DNA biosynthetic process | 22/1272 | 180/18723 | 5.38e-03 | 3.56e-02 | 22 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PHB | SNV | Missense_Mutation | novel | c.590G>C | p.Arg197Thr | p.R197T | P35232 | protein_coding | deleterious(0.02) | possibly_damaging(0.848) | TCGA-A8-A09Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
PHB | insertion | Nonsense_Mutation | novel | c.69_70insTATTCAAAAAGAGCTTCCCAGCCCACTTCCTAGTTGGATGTGC | p.Asn24TyrfsTer11 | p.N24Yfs*11 | P35232 | protein_coding | | | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PHB | insertion | Nonsense_Mutation | novel | c.249_250insTTCTCATAGACAGGGAAATAAGCTCAGGTTGGCTAAGGCTTAGAGAG | p.Asp84PhefsTer3 | p.D84Ffs*3 | P35232 | protein_coding | | | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
PHB | SNV | Missense_Mutation | | c.349N>T | p.Arg117Cys | p.R117C | P35232 | protein_coding | deleterious(0.02) | benign(0.007) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PHB | SNV | Missense_Mutation | | c.466G>A | p.Glu156Lys | p.E156K | P35232 | protein_coding | tolerated(0.36) | benign(0.314) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
PHB | SNV | Missense_Mutation | | c.347N>C | p.Glu116Ala | p.E116A | P35232 | protein_coding | deleterious(0.01) | probably_damaging(0.933) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PHB | SNV | Missense_Mutation | | c.349C>T | p.Arg117Cys | p.R117C | P35232 | protein_coding | deleterious(0.02) | benign(0.007) | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
PHB | SNV | Missense_Mutation | rs377541756 | c.626N>T | p.Ala209Val | p.A209V | P35232 | protein_coding | deleterious(0.04) | benign(0.327) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
PHB | SNV | Missense_Mutation | novel | c.175C>T | p.Pro59Ser | p.P59S | P35232 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AJ-A8CW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PHB | SNV | Missense_Mutation | rs759272172 | c.397N>T | p.Arg133Cys | p.R133C | P35232 | protein_coding | tolerated(0.06) | benign(0.021) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |